Adam R Aluisio1, Derrick Yam2, Jillian L Peters3, Daniel K Cho3, Shiromi M Perera4, Stephen B Kennedy5, Moses Massaquoi5, Foday Sahr6, Michael A Smit7, Tao Liu2, Adam C Levine1. 1. Department of Emergency Medicine, Brown University Alpert Medical School, Rhode Island. 2. Center for Statistical Sciences, Department of Biostatistics, Brown University School of Public Health, Rhode Island. 3. Brown University, Providence, Rhode Island. 4. International Medical Corps, Washington, District of Columbia, Liberia. 5. Ministry of Health, Monrovia, Liberia. 6. Ministry of Defense, Freetown, Sierra Leone. 7. Division of Infectious Diseases, Children's Hospital Los Angeles, California.
Abstract
BACKGROUND: Intravenous fluid (IVF) is a frequently recommended intervention in Ebola virus disease (EVD), yet its impact on patient outcomes remains unclear. METHODS: This retrospective cohort study evaluated patients with EVD admitted to 5 Ebola treatment units (ETUs) in West Africa. The primary outcome was the difference in 28-day survival between cases treated and not treated with IVF. To control for demographic and clinical factors related to both IVF exposure and survival, cases were compared using propensity score matching. To control for time-varying patient and treatment factors over the course of ETU care, a marginal structural proportional hazards model (MSPHM) with inverse probability weighting was used to assess for 28-day survival differences. RESULTS: Among 424 EVD-positive cases with data for analysis, 354 (83.5%) were treated with IVF at some point during their ETU admission. Overall, 146 (41.3%) cases treated with IVF survived, whereas 31 (44.9%) cases not treated with any IVF survived (P = .583). Matched propensity score analysis found no significant difference in 28-day survival between cases treated and not treated with IVF during their first 24 and 48 hours of care. Adjusted MSPHM survival analyses also found no significant difference in 28-day survival for cases treated with IVF (27.3%) compared to those not treated with IVF (26.9%) during their entire ETU admission (P = .893). CONCLUSIONS: After adjustment for patient- and treatment-specific time-varying factors, there was no significant difference in survival among patients with EVD treated with IVF as compared to those not treated with IVF.
BACKGROUND: Intravenous fluid (IVF) is a frequently recommended intervention in Ebola virus disease (EVD), yet its impact on patient outcomes remains unclear. METHODS: This retrospective cohort study evaluated patients with EVD admitted to 5 Ebola treatment units (ETUs) in West Africa. The primary outcome was the difference in 28-day survival between cases treated and not treated with IVF. To control for demographic and clinical factors related to both IVF exposure and survival, cases were compared using propensity score matching. To control for time-varying patient and treatment factors over the course of ETU care, a marginal structural proportional hazards model (MSPHM) with inverse probability weighting was used to assess for 28-day survival differences. RESULTS: Among 424 EVD-positive cases with data for analysis, 354 (83.5%) were treated with IVF at some point during their ETU admission. Overall, 146 (41.3%) cases treated with IVF survived, whereas 31 (44.9%) cases not treated with any IVF survived (P = .583). Matched propensity score analysis found no significant difference in 28-day survival between cases treated and not treated with IVF during their first 24 and 48 hours of care. Adjusted MSPHM survival analyses also found no significant difference in 28-day survival for cases treated with IVF (27.3%) compared to those not treated with IVF (26.9%) during their entire ETU admission (P = .893). CONCLUSIONS: After adjustment for patient- and treatment-specific time-varying factors, there was no significant difference in survival among patients with EVD treated with IVF as compared to those not treated with IVF.
Authors: G Marshall Lyon; Aneesh K Mehta; Jay B Varkey; Kent Brantly; Lance Plyler; Anita K McElroy; Colleen S Kraft; Jonathan S Towner; Christina Spiropoulou; Ute Ströher; Timothy M Uyeki; Bruce S Ribner Journal: N Engl J Med Date: 2014-11-12 Impact factor: 91.245
Authors: Benjamin Jeffs; Paul Roddy; David Weatherill; Olimpia de la Rosa; Claire Dorion; Marta Iscla; Isabel Grovas; Pedro Pablo Palma; Luis Villa; Oscar Bernal; Josefa Rodriguez-Martinez; Barbara Barcelo; Diana Pou; Matthias Borchert Journal: J Infect Dis Date: 2007-11-15 Impact factor: 5.226
Authors: Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy Journal: N Engl J Med Date: 2016-10-13 Impact factor: 91.245
Authors: Allison M Liddell; Richard T Davey; Aneesh K Mehta; Jay B Varkey; Colleen S Kraft; Gebre K Tseggay; Oghenetega Badidi; Andrew C Faust; Katia V Brown; Anthony F Suffredini; Kevin Barrett; Mark J Wolcott; Vincent C Marconi; G Marshall Lyon; Gary L Weinstein; Kenney Weinmeister; Shelby Sutton; Munir Hazbun; César G Albariño; Zachary Reed; Debi Cannon; Ute Ströher; Mark Feldman; Bruce S Ribner; H Clifford Lane; Anthony S Fauci; Timothy M Uyeki Journal: Ann Intern Med Date: 2015-07-21 Impact factor: 25.391
Authors: Elhadj Ibrahima Bah; Marie-Claire Lamah; Tom Fletcher; Shevin T Jacob; David M Brett-Major; Amadou Alpha Sall; Nahoko Shindo; William A Fischer; Francois Lamontagne; Sow Mamadou Saliou; Daniel G Bausch; Barry Moumié; Tim Jagatic; Armand Sprecher; James V Lawler; Thierry Mayet; Frederique A Jacquerioz; María F Méndez Baggi; Constanza Vallenas; Christophe Clement; Simon Mardel; Ousmane Faye; Oumar Faye; Baré Soropogui; Nfaly Magassouba; Lamine Koivogui; Ruxandra Pinto; Robert A Fowler Journal: N Engl J Med Date: 2014-11-05 Impact factor: 91.245
Authors: Tini Garske; Anne Cori; Archchun Ariyarajah; Isobel M Blake; Ilaria Dorigatti; Tim Eckmanns; Christophe Fraser; Wes Hinsley; Thibaut Jombart; Harriet L Mills; Gemma Nedjati-Gilani; Emily Newton; Pierre Nouvellet; Devin Perkins; Steven Riley; Dirk Schumacher; Anita Shah; Maria D Van Kerkhove; Christopher Dye; Neil M Ferguson; Christl A Donnelly Journal: Philos Trans R Soc Lond B Biol Sci Date: 2017-05-26 Impact factor: 6.237
Authors: Adam R Aluisio; Shiromi M Perera; Derrick Yam; Stephanie Garbern; Jillian L Peters; Logan Abel; Daniel K Cho; Dayan Woldemichael; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Tao Liu; Adam C Levine Journal: Trop Med Int Health Date: 2020-01-22 Impact factor: 2.622
Authors: Logan Abel; Shiromi M Perera; Derrick Yam; Stephanie Garbern; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Dayan Woldemichael; Tao Liu; Adam C Levine; Adam R Aluisio Journal: BMC Infect Dis Date: 2022-01-20 Impact factor: 3.090